The balance she needs...

  • The first oral GnRH antagonist combined with add-back therapy in Europe, licensed specifically for uterine fibroids1

  • Balances efficacy and safety1–3

  • Significantly reduces heavy menstrual bleeding2,3
    >85% of women respond to Ryeqo2

  • Significantly reduces pain
    associated with uterine fibroids2,3

  • Significant improvement
    in quality of life4

  • Inhibits ovulation and provides adequate contraception
    after one month of treatment*1

  • Established safety profile1–3

  • Bone health preserved
    during 104 weeks’ treatment1

...for the life she wants.